Obstructive Hypertrophic Cardiomyopathy
📧 Sign up to get email alerts when something new happens for Obstructive Hypertrophic Cardiomyopathy.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2025-04-17FDA Approved: CAMZYOS — Supplemental Application (Myokardia, Inc.)
The FDA approved a supplemental application for CAMZYOS (mavacamten) from Myokardia, Inc., marking an approved update to its labeling or ind…
-
FDA approval · 2023-12-19FDA Approved: CAMZYOS — Supplemental Application (Myokardia, Inc.)
FDA approved a supplemental application for Camzyos (mavacamten) from Myokardia, Inc., advancing regulatory action related to the drug.
-
FDA approval · 2022-04-28FDA Approved: CAMZYOS — Original Application (Myokardia, Inc.)
FDA approved CAMZYOS (mavacamten) from MyoKardia for adults with symptomatic obstructive hypertrophic cardiomyopathy, marking a new mechanis…